Abattis Bioceuticals Accounts Payable

Abattis Bioceuticals (ATTBF) currently reports a accounts payable of $220K as of September 2019. That compares with $220K in the prior-year period — down 1.7% year over year. Use the charts on this page to explore Abattis Bioceuticals's accounts payable history and peer comparisons.

Abattis Bioceuticals's accounts payable decreased from $220K to $220K — a 1.7% year-over-year decrease (period ending September 2019). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Abattis Bioceuticals reported $220K in accounts payable as of September 2019. That compares with $220K in the prior-year period — down 1.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $220K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Abattis Bioceuticals, and consider following ATTBF for alerts when major investors trade the stock.

Abattis Bioceuticals is classified in the Healthcare sector. On accounts payable, it currently shows $220K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ATTBF with unrelated industries.